JP2009534339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534339A5 JP2009534339A5 JP2009505780A JP2009505780A JP2009534339A5 JP 2009534339 A5 JP2009534339 A5 JP 2009534339A5 JP 2009505780 A JP2009505780 A JP 2009505780A JP 2009505780 A JP2009505780 A JP 2009505780A JP 2009534339 A5 JP2009534339 A5 JP 2009534339A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- purin
- propionylamino
- cyclopentane
- ethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WCHCENBRXCRCNM-AXDNMTBYSA-N (1s,2r,3s,5r)-3-amino-5-(2,6-dichloropurin-9-yl)cyclopentane-1,2-diol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O[C@@H]1[C@H](O)[C@@H](N)C[C@H]1N1C2=NC(Cl)=NC(Cl)=C2N=C1 WCHCENBRXCRCNM-AXDNMTBYSA-N 0.000 description 1
- UTIIMMIDWDEPTM-WFFVHEBKSA-N 4-[2-[[9-[(1R,2S,3R,4S)-2,3-dihydroxy-4-(propanoylamino)cyclopentyl]-6-(2,2-diphenylethylamino)purine-2-carbonyl]amino]ethylcarbamoylamino]piperidine-1-carboxylic acid Chemical compound CCC(=O)N[C@H]1C[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NCC(C3=CC=CC=C3)C3=CC=CC=C3)N=C(N=C12)C(=O)NCCNC(=O)NC1CCN(CC1)C(O)=O UTIIMMIDWDEPTM-WFFVHEBKSA-N 0.000 description 1
- LFSOSCRHXHQDSV-WFFVHEBKSA-N 9-[(1r,2s,3r,4s)-2,3-dihydroxy-4-(propanoylamino)cyclopentyl]-6-(2,2-diphenylethylamino)-n-[2-(piperidin-4-ylcarbamoylamino)ethyl]purine-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](NC(=O)CC)C[C@H]1N1C2=NC(C(=O)NCCNC(=O)NC3CCNCC3)=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 LFSOSCRHXHQDSV-WFFVHEBKSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- -1 dihydroxy-4-propionylamino-cyclopentyl Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0607953.7A GB0607953D0 (en) | 2006-04-21 | 2006-04-21 | Organic compounds |
| PCT/EP2007/003436 WO2007121921A2 (en) | 2006-04-21 | 2007-04-19 | Purine derivatives for use as adenosin a2a receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534339A JP2009534339A (ja) | 2009-09-24 |
| JP2009534339A5 true JP2009534339A5 (https=) | 2011-06-23 |
Family
ID=36581050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505780A Pending JP2009534339A (ja) | 2006-04-21 | 2007-04-19 | アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090105476A1 (https=) |
| EP (1) | EP2012760A2 (https=) |
| JP (1) | JP2009534339A (https=) |
| KR (1) | KR20080110923A (https=) |
| CN (1) | CN101426483A (https=) |
| AU (1) | AU2007241344A1 (https=) |
| BR (1) | BRPI0710655A2 (https=) |
| CA (1) | CA2648813A1 (https=) |
| GB (1) | GB0607953D0 (https=) |
| MX (1) | MX2008013418A (https=) |
| RU (1) | RU2008145701A (https=) |
| WO (1) | WO2007121921A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| EP2322525B1 (en) | 2006-04-21 | 2013-09-18 | Novartis AG | Purine derivatives for use as adenosin A2A receptor agonists |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| CA2669108A1 (en) * | 2006-11-10 | 2008-05-15 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009050199A1 (en) * | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine al receptor ligands |
| US20090181934A1 (en) * | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| US9394310B2 (en) | 2010-12-03 | 2016-07-19 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
| US8580762B2 (en) | 2010-12-03 | 2013-11-12 | Epizyme, Inc. | Substituted purine and 7-deazapurine compounds |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| AU2012256237B2 (en) | 2011-05-13 | 2017-01-05 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20150284422A1 (en) | 2012-08-10 | 2015-10-08 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| US9597348B2 (en) | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| US9738679B2 (en) | 2013-03-15 | 2017-08-22 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| CA2949160C (en) | 2014-05-15 | 2023-03-21 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1528382A (en) * | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| US4738954A (en) * | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
| US4954504A (en) * | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
| US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| EA000884B1 (ru) * | 1996-01-02 | 2000-06-26 | Рон-Пуленк Рорер Фармасьютикалз Инк. | Способ получения 2,4-дигидроксипиридина и 2,4-дигидрокси-3-нитропиридина |
| US6376472B1 (en) * | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813535D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| CN1383427A (zh) * | 1998-12-31 | 2002-12-04 | 阿温蒂斯药物公司 | 制备n6－取代的脱氮杂一腺苷衍生物的方法 |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| JP4012070B2 (ja) * | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用 |
| US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
| EP1258247A1 (en) * | 2001-05-14 | 2002-11-20 | Aventis Pharma Deutschland GmbH | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
| US7414036B2 (en) * | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| DE602004006895T2 (de) * | 2003-12-29 | 2008-01-31 | Can-Fite Biopharma Ltd. | Verfahren zur behandlung von multipler sklerose |
| CA2557285A1 (en) * | 2004-03-05 | 2005-09-15 | Cambridge Biotechnology Limited | Adenosine receptor agonists |
| US7825102B2 (en) * | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
| JP2008512457A (ja) * | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| US20080051364A1 (en) * | 2004-11-08 | 2008-02-28 | Pninna Fishman | Therapeutic Treatment of Accelerated Bone Resorption |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| RS52458B (sr) * | 2005-02-04 | 2013-02-28 | Millennium Pharmaceuticals Inc. | Inhibitori e1 aktivirajućih enzima |
| JP5339916B2 (ja) * | 2005-11-30 | 2013-11-13 | キャン−ファイト・バイオファーマ・リミテッド | 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用 |
| CN101410114B (zh) * | 2006-01-26 | 2012-07-04 | 美国政府卫生与公共服务部 | A3腺苷受体别构调节剂 |
| EA024006B1 (ru) * | 2006-02-02 | 2016-08-31 | Миллениум Фармасьютикалз, Инк. | Ингибиторы е1 активирующих ферментов |
| GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| US8008307B2 (en) * | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| CA2669108A1 (en) * | 2006-11-10 | 2008-05-15 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
| US20090181934A1 (en) * | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
-
2006
- 2006-04-21 GB GBGB0607953.7A patent/GB0607953D0/en not_active Ceased
-
2007
- 2007-04-19 AU AU2007241344A patent/AU2007241344A1/en not_active Abandoned
- 2007-04-19 BR BRPI0710655-6A patent/BRPI0710655A2/pt not_active IP Right Cessation
- 2007-04-19 KR KR1020087028380A patent/KR20080110923A/ko not_active Withdrawn
- 2007-04-19 EP EP07724373A patent/EP2012760A2/en not_active Withdrawn
- 2007-04-19 CA CA002648813A patent/CA2648813A1/en not_active Abandoned
- 2007-04-19 MX MX2008013418A patent/MX2008013418A/es not_active Application Discontinuation
- 2007-04-19 JP JP2009505780A patent/JP2009534339A/ja active Pending
- 2007-04-19 CN CNA2007800144345A patent/CN101426483A/zh active Pending
- 2007-04-19 US US12/297,940 patent/US20090105476A1/en not_active Abandoned
- 2007-04-19 WO PCT/EP2007/003436 patent/WO2007121921A2/en not_active Ceased
- 2007-04-19 RU RU2008145701/15A patent/RU2008145701A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534339A5 (https=) | ||
| CN101062932A (zh) | 制备10,11－二氢－10－羟基－5H－二苯并[b,f]氮杂䓬－5－甲酰胺的对映选择性方法及其新晶形 | |
| CN100343227C (zh) | 坦洛新的拆分方法 | |
| CN1882535A (zh) | 2－氧代－1－吡咯烷衍生物的制备方法 | |
| CN1602305A (zh) | 异西酞普兰的制备方法 | |
| CN102964323A (zh) | 一种5-（哌嗪-1-基）苯并呋喃-2-甲酰胺的合成方法 | |
| Sato et al. | Highly enantioselective asymmetric autocatalysis of 2‐alkenyl‐and 2‐vinyl‐5‐pyrimidyl alkanols with significant amplification of enantiomeric excess | |
| JP2008519023A5 (https=) | ||
| JP2009062360A (ja) | シナカルセットの製造方法 | |
| CN114853681A (zh) | 一种嘧啶杂环脒基甲酸酯化合物的制备方法 | |
| CN104164469B (zh) | 一种应用南极假丝酵母脂肪酶b生产替卡格雷手性药物中间体的方法 | |
| CN103304447B (zh) | (s)-卡巴拉汀的合成工艺 | |
| CN1964942A (zh) | 通过分子内烯丙基化制备2－氧代－1－吡咯烷衍生物的方法 | |
| JP4170990B2 (ja) | 光学的に活性であるセリン誘導体の製造方法 | |
| US20100249438A1 (en) | Preparation of escitalopram | |
| CN103254107A (zh) | 一种依泽替米贝类似物及其制备方法 | |
| WO2014139410A1 (zh) | 一种阿折地平中间体的制备方法 | |
| WO2011070585A1 (en) | Processes for preparing rivastigmine, salts and intermediates thereof | |
| CN1247525C (zh) | N－(取代苯基)丙氨酸及其酯的制备方法及其旋光构型体的消旋方法 | |
| CN113620855A (zh) | 一种伊万卡塞中间体ii及其合成方法 | |
| US20110230666A1 (en) | process for the separation of enantiomerically pure compounds | |
| CN1309708C (zh) | 酶化学法合成光学活性氰醇化合物 | |
| CN1071315C (zh) | 新氨基甲酸酯类化合物及其制法 | |
| WO2004011451A1 (ja) | 光学活性１，４−ベンゾジオキサン誘導体の工業的製法 | |
| EP2276739A1 (en) | Process for making montelukast intermediates |